• First Berlin Equity Research reiterated a Buy on Cardiol Therapeutics, trimming its 12-month target price to USD 7.40 from USD 7.50.
• The firm cited MAVERIC reaching its original 110-patient enrollment target ahead of end-September guidance.
• A blinded review showed fewer pericarditis recurrences than expected, prompting a recommendation to expand enrollment to up to 150 patients.
• The change shifts the expected topline readout to mid-2027 from Q1/27, with existing capital seen funding operations into Q1/28.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiol Therapeutics Inc. published the original content used to generate this news brief via EQS News (Ref. ID: rc_26958) on October 02, 2026, and is solely responsible for the information contained therein.